{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:46:32Z","timestamp":1768275992231,"version":"3.49.0"},"reference-count":33,"publisher":"Japanese Association for Laboratory Animal Science","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp. Anim."],"published-print":{"date-parts":[[2021]]},"DOI":"10.1538\/expanim.20-0103","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T22:05:53Z","timestamp":1606341953000},"page":"169-176","source":"Crossref","is-referenced-by-count":16,"title":["Protective effects of taxifolin on pazopanib-induced liver toxicity: an experimental rat model"],"prefix":"10.1538","volume":"70","author":[{"given":"Baran","family":"Akagunduz","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet","family":"Ozer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Capital Health Regional Medical Center, 750 Brunswich Avenue, 08638, Trenton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Ozc\u0131cek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Veysel","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahin","family":"Lac\u0131n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Yeditepe University, 326 Atasehir, 34010, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"\u00d6zkaraca","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Veterinary Medicine, Ataturk University, 12 Yakutiye Avenue, 25000, Erzurum, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulkadir","family":"\u00c7oban","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahad\u0131r","family":"Suleyman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renad","family":"Mammadov","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halis","family":"Suleyman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"439","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pal SK, Hossain DMS, Zhang Q, Frankel PH, Jones JO, Carmichael C, et al.Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile. J Urol.  2015;  193: 1114\u20131121.","DOI":"10.1016\/j.juro.2014.09.110"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Endo M, Nielsen TO. Pazopanib for metastatic soft-tissue sarcoma. Lancet.  2012;  380: 801, author reply 801","DOI":"10.1016\/S0140-6736(12)61440-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Karch A, Koch A, Gr\u00fcnwald V. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. Trials.  2016;  17: 312.","DOI":"10.1186\/s13063-016-1434-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Dinkic C, Eichbaum M, Schmidt M, Grischke EM, Gebauer G, Fricke HC, et al.Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. Gynecol Oncol.  2017;  146: 279\u2013284.","DOI":"10.1016\/j.ygyno.2017.05.013"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Sch\u00f6ffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol.  2009;  27: 3126\u20133132.","DOI":"10.1200\/JCO.2008.21.3223"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Pick AM, Nystrom KK. Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Ther.  2012;  34: 511\u2013520.","DOI":"10.1016\/j.clinthera.2012.01.014"},{"key":"7","unstructured":"7. Administration USF and Pazopanib D. (Votrient) prescribing information.  2010."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zhang J, Salminen A, Yang X, Luo Y, Wu Q, White M, et al. Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria. Arch Toxicol.  2017;  91: 2921\u20132938.","DOI":"10.1007\/s00204-016-1918-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wang YK, Yang XN, Liang WQ, Xiao Y, Zhao Q, Xiao XR, et al. A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice. Xenobiotica.  2019;  49: 655\u2013670.","DOI":"10.1080\/00498254.2018.1489167"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yang M, Ruan J, Gao H, Li N, Ma J, Xue J, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol.  2017;  91: 3913\u20133925.","DOI":"10.1007\/s00204-017-2013-y"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Choudhury Y, Toh YC, Xing J, Qu Y, Poh J, Li H, et al. Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Sci Rep.  2017;  7: 41238.","DOI":"10.1038\/srep46391"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mingard C, Paech F, Bouitbir J, Kr\u00e4henb\u00fchl S. Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. J Appl Toxicol.  2018;  38: 418\u2013431.","DOI":"10.1002\/jat.3551"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kumar S, Pandey AK. 2013. Chemistry and biological activities of flavonoids: an overview. <i>Scientific World Journal<\/i> 2013: 162750.","DOI":"10.1155\/2013\/162750"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. M\u00fclek M, Seefried L, Genest F, H\u00f6gger P. Distribution of constituents and metabolites of maritime pine bark extract (Pycnogenol\u00ae) into serum, blood cells, and synovial fluid of patients with severe osteoarthritis: a randomized controlled trial. Nutrients.  2017;  9: 443.","DOI":"10.3390\/nu9050443"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Slimestad R, Fossen T, V\u00e5gen IM. Onions: a source of unique dietary flavonoids. J Agric Food Chem.  2007;  55: 10067\u201310080.","DOI":"10.1021\/jf0712503"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol.  2009;  61: 223\u2013242.","DOI":"10.1016\/j.etp.2008.09.003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Zhang ZR, Al Zaharna M, Wong MMK, Chiu SK, Cheung HY. Taxifolin enhances andrographolide-induced mitotic arrest and apoptosis in human prostate cancer cells via spindle assembly checkpoint activation. PLoS One.  2013;  8: e54577.","DOI":"10.1371\/journal.pone.0054577"},{"key":"18","doi-asserted-by":"publisher","unstructured":"19. Manigandan K, Manimaran D, Jayaraj RL, Elangovan N, Dhivya V, Kaphle A. Taxifolin curbs NF-\u03baB-mediated Wnt\/\u03b2-catenin signaling via up-regulating Nrf2 pathway in experimental colon carcinogenesis. Biochimie.  2015;  119: 103\u2013112.","DOI":"10.1016\/j.biochi.2015.10.014"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20. Dok-Go H, Lee KH, Kim HJ, Lee EH, Lee J, Song YS, et al. Neuroprotective effects of antioxidative flavonoids, quercetin, (+)-dihydroquercetin and quercetin 3-methyl ether, isolated from Opuntia ficus-indica var. saboten. Brain Res.  2003;  965: 130\u2013136.","DOI":"10.1016\/S0006-8993(02)04150-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21. Zhou S, Shao Y, Fu J, Xiang L, Zheng Y, Li W. Characterization and Quantification of Taxifolin Related Flavonoids in Larix olgensis Henry Var. koreana Nakai Extract Analysis and its Antioxidant Activity Assay. Int J Pharmacol.  2018;  14: 534\u2013545.","DOI":"10.3923\/ijp.2018.534.545"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22. Erhan E, Bayram R, Cimen FK, Altuner D, Seckin E, Kurt N, et al. The effect of taxifolin on cisplatin induced oxidative cochlear damage in rats: biochemical and histopathological examination. Acta Pol Pharm Res. 2019;  76: 895\u2013900.","DOI":"10.32383\/appdr\/110616"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem.  1979;  95: 351\u2013358.","DOI":"10.1016\/0003-2697(79)90738-3"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman\u2019s reagent. Anal Biochem.  1968;  25: 192\u2013205.","DOI":"10.1016\/0003-2697(68)90092-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem.  2005;  38: 1103\u20131111.","DOI":"10.1016\/j.clinbiochem.2005.08.008"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem.  2004;  37: 112\u2013119.","DOI":"10.1016\/j.clinbiochem.2003.10.014"},{"key":"26","doi-asserted-by":"publisher","unstructured":"27. van der Graaf WTA, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. EORTC Soft Tissue and Bone Sarcoma GroupPALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet.  2012;  379: 1879\u20131886.","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med.  2013;  369: 722\u2013731.","DOI":"10.1056\/NEJMoa1303989"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol.  2010;  28: 1061\u20131068.","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30. Kapadia S, Hapani S, Wu S. Risk of high-grade liver toxicity with pazopanib in patients with cancer: A meta-analysis. J Clin Oncol.  2011;  29: 4595.","DOI":"10.1200\/jco.2011.29.15_suppl.4595"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31. Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, et al.Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol.  2011;  54: 1237\u20131243.","DOI":"10.1016\/j.jhep.2010.09.028"},{"key":"31","doi-asserted-by":"crossref","unstructured":"33. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med.  1996;  20: 933\u2013956.","DOI":"10.1016\/0891-5849(95)02227-9"},{"key":"32","doi-asserted-by":"crossref","unstructured":"34. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci.  2016;  5: e47.","DOI":"10.1017\/jns.2016.41"},{"key":"33","doi-asserted-by":"crossref","unstructured":"35. Weidmann AE. Dihydroquercetin: More than just an impurity?Eur J Pharmacol.  2012;  684: 19\u201326.","DOI":"10.1016\/j.ejphar.2012.03.035"}],"container-title":["Experimental Animals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/expanim\/70\/2\/70_20-0103\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T03:39:20Z","timestamp":1621049960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/expanim\/70\/2\/70_20-0103\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1538\/expanim.20-0103","relation":{},"ISSN":["1341-1357","1881-7122"],"issn-type":[{"value":"1341-1357","type":"print"},{"value":"1881-7122","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}